Skip to main content
  • Contact Us
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Carmat

Evaluate

Thumbnail
June 15, 2022

To back, or back away from, digital health?

Some medtech venture investors are taken with the promise of digital technologies, while others find them easy to resist.

Thumbnail
July 19, 2021

Carmat hits the big time

Article image
Vantage logo
December 23, 2020

A joyeux Noël for Carmat

Article image
Vantage logo
August 14, 2020

Medicare mulls broadening heart pump reimbursement

Article image
Vantage logo
September 03, 2019

ESC 2019 – Carmat is stout-hearted in the face of a challenging schedule

Carmat says its artificial heart is the best such device in existence. But time is short, and so is money.

Article image
Vantage logo
January 15, 2019

Carmat’s heart sinks with another delay

Despite encouraging interim pivotal data, Carmat’s artificial heart seems as far from market as ever.

Vantage logo
May 05, 2017

Snippet roundup: Novartis's allogeneic CAR-T drive and Astra's IL-4 interest

Vantage logo
February 10, 2017

Snippet roundup: Pressure is on for Axovant and Glaxo

Vantage logo
December 01, 2016

Patient death halts Carmat trial

Vantage logo
August 02, 2016

Interview – Carmat’s heart approaches market as rival hits the buffers

Vantage logo
January 15, 2015

Mid-cap medtech shares rise in 2014 on deals and the possibility of more

  • Load More

Latest Reports

July 27, 2023

H1 Round Up: The haves and the have-nots

July 21, 2023

ADA/EASL eBook

View more...

Editor's Picks

Vantage logo
July 03, 2023

Astrazeneca and Daiichi’s big reveal disappoints

Vantage logo
July 13, 2023

Pharma finds a way to gain weight

Vantage logo
July 03, 2023

Protagonist investors flake as psoriasis pill disappoints

Vantage logo
June 29, 2023

Approaching datasets for big pharma

Vantage logo
June 27, 2023

Nkarta goes back to basics

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up